Jeuveau/Nabota 100 IU (Korean Packaging) 1 vial

Administer intramuscular injections using established anatomical mapping and individualized dosing per muscle strength and treatment goals.
Reconstitute and inject according to manufacturer instructions; distribute units across standardized points to optimize symmetry and effect.
For safety, avoid intravascular injection, inject slowly, and adhere to aseptic technique. Professional use only.

Advise patients to avoid alcohol for at least 24 hours before and after treatment to limit vasodilation-related bruising and swelling and to support optimal recovery.

Not recommended in pregnancy. Controlled safety data are lacking, and systemic exposure risks cannot be excluded. Elective aesthetic procedures should be postponed until after delivery.

Botulinum Toxin Type A (prabotulinumtoxinA) in a lyophilized powder for reconstitution; formulated for reliable diffusion characteristics and predictable aesthetic outcomes when used by qualified clinicians.

Common: transient injection-site pain, redness, swelling, bruising, headache, or localized tenderness (typically resolving within several days).
Rare but serious: eyelid/brow ptosis, asymmetry, diplopia; hypersensitivity reactions; and symptoms suggestive of toxin spread (e.g., dysphagia, dysphonia, breathing difficulty). These require immediate medical evaluation. Post-procedure, avoid rubbing or massaging treated areas and follow provider aftercare.

Botulinum toxin type A inhibits acetylcholine release at the neuromuscular junction by cleaving SNARE proteins (e.g., SNAP-25), producing a reversible chemodenervation of the targeted muscles and a visible reduction in dynamic lines. Function gradually returns as neuromuscular signaling is restored.

Not advised while breastfeeding due to insufficient data on toxin/metabolite transfer into breast milk and potential infant risk. Defer treatment until breastfeeding has concluded.